LLY

1,132.64

+3.8%↑

JNJ

227.98

+1.77%↑

ABBV

223.43

+2.02%↑

UNH

396.26

+3.41%↑

MRK

119.26

+3.41%↑

LLY

1,132.64

+3.8%↑

JNJ

227.98

+1.77%↑

ABBV

223.43

+2.02%↑

UNH

396.26

+3.41%↑

MRK

119.26

+3.41%↑

LLY

1,132.64

+3.8%↑

JNJ

227.98

+1.77%↑

ABBV

223.43

+2.02%↑

UNH

396.26

+3.41%↑

MRK

119.26

+3.41%↑

LLY

1,132.64

+3.8%↑

JNJ

227.98

+1.77%↑

ABBV

223.43

+2.02%↑

UNH

396.26

+3.41%↑

MRK

119.26

+3.41%↑

LLY

1,132.64

+3.8%↑

JNJ

227.98

+1.77%↑

ABBV

223.43

+2.02%↑

UNH

396.26

+3.41%↑

MRK

119.26

+3.41%↑

Начало・Списък с акции・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Отворен

17.32 10.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

15.59

Максимум

17.77

Ключови измерители
By Trading Economics
Приходи	-6.4M -20M
Продажби	-807K 71M
EPS	-0.13
Марж на печалбата	-28.24
Служители	624
EBITDA	-7.9M -14M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+33.22% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	121M 2.4B
Предишно отваряне	7
Предишно затваряне	17.32

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.06.2026 г., 23:22 ч. UTC

Печалби

Значими двигатели на пазара

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3.06.2026 г., 23:09 ч. UTC

Горещи акции

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3.06.2026 г., 20:51 ч. UTC

Печалби

Costco Reports 15% Sales Growth in May

3.06.2026 г., 20:43 ч. UTC

Печалби

Broadcom 2Q Revenue Climbs on AI Chip Demand

3.06.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3.06.2026 г., 23:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.06.2026 г., 23:35 ч. UTC

Пазарно говорене

Oil Futures Fall on Possible Technical Correction -- Market Talk

3.06.2026 г., 23:15 ч. UTC

Пазарно говорене

Печалби

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3.06.2026 г., 22:08 ч. UTC

Горещи акции

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3.06.2026 г., 21:54 ч. UTC

Пазарно говорене

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3.06.2026 г., 21:18 ч. UTC

Печалби

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3.06.2026 г., 21:15 ч. UTC

Печалби

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3.06.2026 г., 21:13 ч. UTC

Печалби

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3.06.2026 г., 21:13 ч. UTC

Печалби

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3.06.2026 г., 21:12 ч. UTC

Печалби

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3.06.2026 г., 21:09 ч. UTC

Печалби

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3.06.2026 г., 21:03 ч. UTC

Печалби

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.06.2026 г., 20:43 ч. UTC

Печалби

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3.06.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3.06.2026 г., 20:37 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3.06.2026 г., 20:35 ч. UTC

Печалби

Broadcom Stock Falls Despite Record Results -- Barrons.com

3.06.2026 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3.06.2026 г., 20:17 ч. UTC

Печалби

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3.06.2026 г., 20:17 ч. UTC

Печалби

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3.06.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3.06.2026 г., 20:15 ч. UTC

Печалби

Broadcom 2Q Adj EPS $2.44 >AVGO

3.06.2026 г., 20:15 ч. UTC

Печалби

Broadcom 2Q EPS $1.91 >AVGO

3.06.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

3.06.2026 г., 20:15 ч. UTC

Печалби

Broadcom 2Q Rev $22.19B >AVGO

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

33.22% нагоре

12-месечна прогноза

Среден 20.17 USD 33.22%

Висок 22 USD

Нисък 18 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Adaptive Biotechnologies Corp през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.